Added to YB: 2024-07-18
Pitch date: 2024-07-16
ARQT [neutral]
Arcutis Biotherapeutics, Inc.
+177.7%
current return
Author Info
Microceph reports is an ex-long/short hedge fund investor sharing their healthcare investment musings. Sign up for the newsletter.
Company Info
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Market Cap
$3.1B
Pitch Price
$10.45
Price Target
N/A
Dividend
N/A
EV/EBITDA
-92.02
P/E
-71.30
EV/Sales
9.39
Sector
Biotechnology
Category
growth
$ARQT - selling amid the froth (foam)
ARQT: Newly approved derm product ZORYVE for seb derm. $350M cap, $228M cash. Q3 rev $8M, 110K scripts. Potential $600M sales (1.5M patients). Foam formulation advantage. Risks: weak commercial execution, competition. Upside: blockbuster potential, takeover. Currently $9, fair value $9-10 based on $600M sales.
Read full article (4 min)